Mercy Investment activist shareholder proposal on cap alloc/R&D
Key Questions
What is Mercy Investment's activist proposal for AbbVie?
Mercy Investment challenges AbbVie's capital allocation, R&D spending, and the $1.4B Durham manufacturing capex post-Humira patent loss. They propose an independent chair at the 2026 AGM.
What are the details of AbbVie's $1.4B Durham investment?
AbbVie is investing $1.4 billion in a 185-acre manufacturing site in Durham, NC, creating over 730 jobs. This follows a $100 billion U.S. R&D and capital pledge.
What is CEO Robert Michael's compensation at AbbVie?
CEO Michael's 2025 compensation is $32.5 million, up significantly, with 75% tied to performance amid $61B market cap driven by Skyrizi and Rinvoq. This is among notable pharma CEO pay hikes.
How does Mercy view AbbVie's valuation?
Mercy estimates AbbVie is undervalued by 17-44%, with potential M&A value at $33.6B. They question post-Humira capital decisions.
What is the context of Mercy Investment's shareholder activism?
As an activist shareholder, Mercy focuses on optimizing cap alloc and R&D post-Humira, amid investments like Durham and high CEO pay. AbbVie selected North Carolina for the new facility announced April 22, 2026.
Mercy challenges cap alloc/R&D/$1.4B Durham mfg capex (730+ jobs) post-Humira; indep chair 2026 AGM; CEO Michael $32.5M comp +75% tied $61B/Skyrizi/Rinvoq; 17-44% undervalue/M&A $33.6B.